Braftovi® (encorafenib) Capsules for BRAF V600–Mutant Melanoma and Colorectal Cancer

What Braftovi® Is and How It Works

Braftovi (encorafenib) is an oral BRAF kinase inhibitor used for certain BRAF V600–mutant cancers. It is approved for unresectable or metastatic melanoma with BRAF V600E or V600K mutations when used with binimetinib, and for metastatic colorectal cancer with a BRAF V600E mutation when used with cetuximab. YouDrugstore is a licensed Canadian pharmacy headquartered in Manitoba; prescriptions are reviewed by licensed pharmacists before dispensing. Many shoppers compare Braftovi price options to manage costs, including those paying Braftovi without insurance.

Encorafenib blocks mutated BRAF proteins in the MAPK/ERK pathway. This helps slow tumor cell growth in cancers driven by BRAF V600 alterations. Braftovi comes as 75 mg capsules (encorafenib 75mg). Some patients and clinicians also track Braftovi Mektovi effectiveness data in melanoma and pair encorafenib with cetuximab in colorectal cancer. We also work with vetted international partner pharmacies to source authentic brand medications across a broad range at budget-friendly prices.

Typical dosing is once daily, with or without food. For melanoma, encorafenib is used with binimetinib. For colorectal cancer, encorafenib is used with cetuximab. The care team selects the regimen and monitors response and tolerability. See our overview article, Braftovi® 75 Mg Uses Dosage And Side Effects, for more detail.

Dosage and Usage

• Form: oral capsules, 75 mg strength (encorafenib 75mg).
• Melanoma (with binimetinib): commonly 450 mg encorafenib once daily plus binimetinib 45 mg twice daily.
• Colorectal cancer (with cetuximab): commonly 300 mg encorafenib once daily plus cetuximab per labeling.
• Take at the same time each day, with or without food.
• Swallow capsules whole; do not crush, chew, or open.
• If vomiting occurs after a dose, do not take an extra dose; resume next scheduled dose.
• Missed dose: if the next dose is due within 12 hours, skip the missed dose; otherwise take it when remembered.
• Drug interactions: strong CYP3A4 inhibitors/inducers, grapefruit, and QT-prolonging drugs may require caution or avoidance.
• Monitoring may include skin exams, liver tests, ocular checks, ECGs, and electrolyte panels.

• Store your capsules at 20–25°C (68–77°F); short excursions 15–30°C (59–86°F) are acceptable.
• Keep the bottle tightly closed with the desiccant; protect from moisture.
• Store in the original container; do not repackage into weekly pill boxes if humidity is high.
• For travel, keep your medicine in your carry-on with the pharmacy label.
• Carry extra doses and a copy of your prescription in case of delays.
• Avoid leaving your medication in a hot car or in direct sunlight.

Benefits and Savings

Braftovi helps control tumors driven by BRAF V600 mutations by targeting the key driver pathway. In melanoma, pairing encorafenib with binimetinib has shown improved response rates and progression-free survival in trials. In metastatic colorectal cancer, adding encorafenib to cetuximab improves outcomes over standard chemotherapy in BRAF V600E–mutant disease. Oral dosing offers convenience compared with some infusion-based regimens. Patients paying Braftovi without insurance often seek predictable monthly costs and clear support for timely refills.

Ordering is available online, and you can call during posted office hours if needed. Expect Canadian pricing with typical 60–80% savings versus common US cash prices. Multi-month supplies and periodic bulk promotions can lower the per-month Braftovi cost. You may set simple reorder reminders to avoid treatment gaps and plan ahead for travel or clinic visits.

Looking for deals? See current Braftovi coupon options on our promotions page.

Side Effects and Safety

• Common: fatigue, nausea, vomiting, abdominal pain, decreased appetite, constipation or diarrhea.
• Musculoskeletal: arthralgia, myalgia, muscle spasms, elevated creatine kinase (more often with MEK inhibitor).
• Skin: rash, dry skin, pruritus, photosensitivity; acneiform rash is more common with cetuximab.
• Liver: elevated AST/ALT; periodic monitoring is recommended.
• Ocular: blurred vision, uveitis; report new eye symptoms promptly.
• Cardiac/QT: palpitations, dizziness; ECG monitoring may be used.
• Electrolytes: low magnesium or potassium may occur, especially with EGFR inhibitors.
• Other: headache, cough, fever, peripheral edema.

Serious risks can include hemorrhage, new primary cutaneous malignancies, non-cutaneous malignancies, severe photosensitivity, uveitis or retinal problems, QT prolongation, hepatotoxicity, and embryo-fetal toxicity. Clinicians may interrupt, reduce, or stop therapy for significant toxicity. Use effective contraception during treatment and for the recommended period after the last dose. Report sudden vision changes, severe skin reactions, chest pain, or syncope urgently.

Onset Time

Time to response varies by cancer type, burden of disease, prior therapy, and combination partner. In melanoma studies, the median time to response with encorafenib plus binimetinib was around 1–2 months. In colorectal cancer, responses with encorafenib plus cetuximab often appear within the first two cycles. Symptom changes may lag behind imaging. Adverse effects can begin within days to weeks and often stabilize after the first month as dosing is optimized.

Durability of benefit also varies. Some patients experience durable control for many months; others may need a switch in therapy sooner due to progression or intolerance. Regular assessments help guide whether to continue, adjust, or change regimens.

Compare With Alternatives

Other BRAF-targeted options for BRAF V600–mutant melanoma include dabrafenib plus trametinib and vemurafenib plus cobimetinib. Regimens differ by dosing frequency, side effect profile, and drug–drug interactions. Discuss prior tolerability, comorbidities, and treatment goals when comparing options.

For BRAF V600E–mutant metastatic colorectal cancer, encorafenib with an EGFR inhibitor (cetuximab) is a standard targeted approach. Alternative strategies may include chemotherapy backbones, often with biologics, based on treatment history and molecular profile. For a broader overview of oncology therapies, see Cancer Drugs List Common Medications And Their Uses.

If you plan to buy encorafenib or compare encorafenib order options, consider clinic administration needs for partner medicines like cetuximab, which requires infusion scheduling.

Combination Therapy

• Melanoma: encorafenib plus binimetinib (BRAFTOVI + MEKTOVI) is standard for BRAF V600E/K–mutant disease.
• Colorectal cancer: encorafenib plus cetuximab is used for BRAF V600E–mutant disease after prior therapy.
• Dose adjustments may reduce toxicity risks such as ocular events, liver enzyme elevations, or QT prolongation.
• Monitor for overlapping side effects when combining with EGFR or MEK inhibitors (e.g., rash, diarrhea, CPK elevation).
• Review other medications for CYP3A4 interactions and QT-prolonging potential.

Patient Suitability and Cost-Saving Tips

Braftovi is intended for tumors with a confirmed BRAF V600 mutation. It should not be used in cancers without a BRAF V600 alteration. Suitability depends on cancer type, stage, prior therapies, organ function, and planned partner drugs. People with significant QT prolongation, uncontrolled electrolyte abnormalities, active ocular disease, or severe hepatic impairment may need extra caution or alternative plans.

Sun protection helps reduce photosensitivity reactions. Regular skin checks can detect new primary skin cancers early. Eye symptoms such as blurred vision or photophobia should be evaluated promptly. Avoid strong CYP3A4 inducers or inhibitors where possible, and avoid grapefruit products.

To manage costs, compare Braftovi cost across strengths and pack sizes. Watch for periodic discount Braftovi promotions and subscribe to reorder reminders. Multi-month supply options can lower the average monthly Braftovi cash price. Customers paying Braftovi out of pocket can often save on Braftovi versus US pharmacy rates by using Canadian pricing. When seeking a Braftovi discount, review total expenses, including clinic-administered partner drugs.

Authoritative Sources

See the European Medicines Agency Braftovi EPAR for assessment details and indication summaries. The manufacturer page provides product information: Pfizer Braftovi Product Page. Canadian regulatory information is available via Health Canada’s Drug Product Database.

Order Braftovi® from Youdrugstore: add to cart, upload your prescription, and we ship with prompt, express shipping.

This content is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment. Always consult your healthcare provider about your specific situation.